Rifampicin Resistance in S. Aureus During and After Treatment for Latent Tuberculosis
Acquisition and Persistence of Rifampicin Resistance in Staphylococcus Aureus During and After Treatment for Latent Tuberculosis
Region Skane
100 participants
Sep 30, 2021
OBSERVATIONAL
Conditions
Summary
Two commonly used treatments for latent tuberculosis infection are either 4 months rifampicin or 6-9 months isoniazid. The invistigators will study the risk of acquisition of rifampicin resistance in commensal Staphylococcus aureus in persons treated with rifampicin versus in persons treated with isoniazide. Through repeated swab cultures before, during, and after treatment the investigators will also investigate potential accumulation of mutations associated with rifampicin resistance over time. Finally, household contacts to persons with rifampicin-resistant S. aureus will be examined to investigate whether onward transmission of rifampicin-resistant S. aureus occurs within households.
Eligibility
Inclusion Criteria3
- diagnosed with latent tuberculosis
- prescribed either 4 months rifampicin or 6-9 months isoniazide
- informed consent
Exclusion Criteria1
- none
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
No intervention is part of the study protocol. The choice of treatment for latent tuberculosis is is made by the treating physician.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05073926